Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
53 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Emphysema - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Emphysema - Pipeline Review, H2 2014', provides an overview of the Emphysema's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Emphysema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emphysema and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Emphysema - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Emphysema and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Emphysema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Emphysema pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Emphysema - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Emphysema pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Emphysema Overview 6 Therapeutics Development 7 Pipeline Products for Emphysema - Overview 7 Pipeline Products for Emphysema - Comparative Analysis 8 Emphysema - Therapeutics under Development by Companies 9 Emphysema - Therapeutics under Investigation by Universities/Institutes 10 Emphysema - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Emphysema - Products under Development by Companies 14 Emphysema - Products under Investigation by Universities/Institutes 15 Emphysema - Companies Involved in Therapeutics Development 16 Angion Biomedica Corp. 16 Boehringer Ingelheim GmbH 17 Intrexon Corporation 18 Kamada Ltd. 19 Protalix BioTherapeutics, Inc. 20 Emphysema - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Combination Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 (olodaterol + tiotropium bromide) - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Alpha-1 Antitrypsin With rHuPH20 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 alpha-1-proteinase inhibitor (human) - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 BB-3 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Monoclonal Antibody to Inhibit EMAP II for Emphysema - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 PRX-107 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecules to Inhibit RAR-Gamma for Emphysema and Bronchopulmonary Dysplasia - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 TRN-101 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Emphysema - Recent Pipeline Updates 44 Emphysema - Dormant Projects 50 Emphysema - Product Development Milestones 51 Featured News & Press Releases 51 Jun 20, 2013: Protalix BioTherapeutics Reveals Information For Emphysema Drug, PRX-107 51 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 53 Disclaimer 53
List of Tables Number of Products under Development for Emphysema, H2 2014 7 Number of Products under Development for Emphysema - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Late Stage Development, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Emphysema - Pipeline by Angion Biomedica Corp., H2 2014 16 Emphysema - Pipeline by Boehringer Ingelheim GmbH, H2 2014 17 Emphysema - Pipeline by Intrexon Corporation, H2 2014 18 Emphysema - Pipeline by Kamada Ltd., H2 2014 19 Emphysema - Pipeline by Protalix BioTherapeutics, Inc., H2 2014 20 Assessment by Monotherapy Products, H2 2014 21 Assessment by Combination Products, H2 2014 22 Number of Products by Stage and Target, H2 2014 24 Number of Products by Stage and Mechanism of Action, H2 2014 26 Number of Products by Stage and Route of Administration, H2 2014 28 Number of Products by Stage and Molecule Type, H2 2014 30 Emphysema Therapeutics - Recent Pipeline Updates, H2 2014 44 Emphysema - Dormant Projects, H2 2014 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.